{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:40:59Z","timestamp":1787244059146,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.7759\/cureus.51405","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T12:16:50Z","timestamp":1704025010000},"source":"Crossref","is-referenced-by-count":11,"title":["Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness"],"prefix":"10.7759","author":[{"given":"Christian  K","family":"Kerut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell  J","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles  P","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilee  J","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline  R","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Amarasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Willett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu RM","year":"2020","unstructured":"Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020, 27:1. 10.1186\/s12929-019-0592-z","journal-title":"J Biomed Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2110-5","article-title":"First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics\/safety in healthy subjects and patients with moderate-to-severe psoriasis","volume":"72","author":"Zhuang Y","year":"2016","unstructured":"Zhuang Y, Calderon C, Marciniak SJ Jr, et al.. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics\/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016, 72:1303-10. 10.1007\/s00228-016-2110-5","journal-title":"Eur J Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0265-6","article-title":"Guselkumab for the treatment of psoriasis","volume":"32","author":"Machado \u00c1","year":"2018","unstructured":"Machado \u00c1, Torres T. Guselkumab for the treatment of psoriasis. BioDrugs. 2018, 32:119-28. 10.1007\/s40259-018-0265-6","journal-title":"BioDrugs"},{"key":"ref4","unstructured":"TREMFYA\u00ae (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis. (2023). Accessed. March 19, 2023: https:\/\/www.jnj.com\/tremfya-guselkumab-approved-by-u-s-food-and-drug-administration-as-the-first-selective-interleuki...."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19694","article-title":"Clinically uninvolved but not healthy-The skin of patients with atopic dermatitis is primed for itch and inflammation","author":"Moon S","year":"2023","unstructured":"Moon S, Stasikowska-Kanicka O, W\u0105growska-Danilewicz M, Hawro M, Metz M, Maurer M, Hawro T. Clinically uninvolved but not healthy-The skin of patients with atopic dermatitis is primed for itch and inflammation. J Eur Acad Dermatol Venereol. 2023, 10.1111\/jdv.19694","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","article-title":"Diagnosing psoriatic arthritis from the dermatologist's view","volume":"3","author":"Cho HH","year":"2013","unstructured":"Cho HH, Kim BS. Diagnosing psoriatic arthritis from the dermatologist's view. J Lifestyle Med. 2013, 3:85-90.","journal-title":"J Lifestyle Med"},{"key":"ref7","article-title":"Psoriasis and psoriatic arthritis","volume":"10","author":"Cather JC","year":"2017","unstructured":"Cather JC, Young M, Bergman MJ. Psoriasis and psoriatic arthritis. J Clin Aesthet Dermatol. 2017, 10:S16-25.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang K","year":"2021","unstructured":"Yang K, Oak AS, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021, 22:173-92. 10.1007\/s40257-020-00578-0","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1063","article-title":"Population pharmacokinetic modeling of guselkumab, a human IgG1\u03bb monoclonal antibody targeting IL-23, in patients with moderate to severe plaque psoriasis","volume":"58","author":"Yao Z","year":"2018","unstructured":"Yao Z, Hu C, Zhu Y, et al.. Population pharmacokinetic modeling of guselkumab, a human IgG1\u03bb monoclonal antibody targeting IL-23, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2018, 58:613-27. 10.1002\/jcph.1063","journal-title":"J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin DA","year":"2013","unstructured":"Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013, 133:17-26. 10.1038\/jid.2012.194","journal-title":"J Invest Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14034","article-title":"Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris","volume":"174","author":"Chiricozzi A","year":"2016","unstructured":"Chiricozzi A, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, et al.. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016, 174:136-45. 10.1111\/bjd.14034","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030654","article-title":"Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the management of psoriasis","volume":"14","author":"Rodr\u00edguez-Fern\u00e1ndez K","year":"2022","unstructured":"Rodr\u00edguez-Fern\u00e1ndez K, Mangas-Sanju\u00e1n V, Merino-Sanju\u00e1n M, Martorell-Calatayud A, Mateu-Puchades A, Climente-Mart\u00ed M, Gras-Colomer E. Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the management of psoriasis. Pharmaceutics. 2022, 14:654. 10.3390\/pharmaceutics14030654","journal-title":"Pharmaceutics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.3965","article-title":"Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis","volume":"31","author":"Chiricozzi A","year":"2021","unstructured":"Chiricozzi A, Costanzo A, Fargnoli MC, et al.. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis. Eur J Dermatol. 2021, 31:3-16. 10.1684\/ejd.2021.3965","journal-title":"Eur J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER- 2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease PJ","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al.. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER- 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020, 395:1126-36. 10.1016\/S0140-6736(20)30263-4","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.42010","article-title":"Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin\u201023, through two years: Results from a phase III, randomized, double\u2010blind, placebo\u2010controlled study conducted in biologic\u2010naive patients with active psoriatic arthritis","volume":"74","author":"McInnes IB","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al.. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin\u201023, through two years: Results from a phase III, randomized, double\u2010blind, placebo\u2010controlled study conducted in biologic\u2010naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022, 74:475-85. 10.1002\/art.42010","journal-title":"Arthritis Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/msc.1694","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","volume":"20 Suppl 1","author":"Fragoulis GE","year":"2022","unstructured":"Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskeletal Care. 2022, 20 Suppl 1:S12-21. 10.1002\/msc.1694","journal-title":"Musculoskeletal Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials","volume":"71","author":"Huang X","year":"2023","unstructured":"Huang X, Shentu H, He Y, Lai H, Xu C, Chen M, Zhu H. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023, 71:505-15. 10.1007\/s12026-023-09366-4","journal-title":"Immunol Res"},{"key":"ref18","article-title":"Psoriatic arthritis","author":"Tiwari V","year":"2023","unstructured":"Tiwari V, Brent LH. Psoriatic arthritis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease P","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, et al.. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018, 77:890-7. 10.1136\/annrheumdis-2017-212687","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock JP","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, et al.. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012, 18:1069-76. 10.1038\/nm.2817","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12936","article-title":"Frequency of skin cancer among psoriasis, vitiligo, and mycosis fungoides patients treated with narrowband ultraviolet B phototherapy","author":"Mimouni I","year":"2023","unstructured":"Mimouni I, Shulman J, Unes AA, Pavlovsky L, Pavlotsky F. Frequency of skin cancer among psoriasis, vitiligo, and mycosis fungoides patients treated with narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2023, 10.1111\/phpp.12936","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212594","article-title":"Guselkumab for the treatment of psoriasis - evidence to date","volume":"8","author":"Nogueira M","year":"2019","unstructured":"Nogueira M, Torres T. Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context. 2019, 8:212594. 10.7573\/dic.212594","journal-title":"Drugs Context"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata M","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020, 21:1690. 10.3390\/ijms21051690","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa- 2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The","volume":"392","author":"Gordon KB","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al.. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa- 2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The. Lancet. 2018, 392:650-61. 10.1016\/S0140-6736(18)31713-6","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER- 1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar A","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al.. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER- 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020, 395:1115-25. 10.1016\/S0140-6736(20)30265-8","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash P","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, et al.. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018, 20:47. 10.1186\/s13075-018-1551-x","journal-title":"Arthritis Res Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen LE","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, et al.. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022, 81:225-31. 10.1136\/annrheumdis-2021-221019","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r A","year":"2022","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, et al.. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022, 81:351-8. 10.1136\/annrheumdis-2021-221048","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes IB","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al.. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013, 382:780-9. 10.1016\/S0140-6736(13)60594-2","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin C","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et al.. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014, 73:990-9. 10.1136\/annrheumdis-2013-204655","journal-title":"Ann Rheum Dis"},{"key":"ref31","article-title":"Global Report on Psoriasis","author":"Michalek IM","year":"2016","unstructured":"Michalek IM, Loring B, John SM. Global Report on Psoriasis. WHO, 2016."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths CE","year":"2021","unstructured":"Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. Lancet. 2021, 397:1301-15. 10.1016\/S0140-6736(20)32549-6","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths CE","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007, 370:263-71. 10.1016\/S0140-6736(07)61128-3","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1974.01630020023005","article-title":"Natural history of psoriasis in 61 twin pairs","volume":"109","author":"Farber EM","year":"1974","unstructured":"Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974, 109:207-11. 10.1001\/archderm.1974.01630020023005","journal-title":"Arch Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genom.6.080604.162324","article-title":"The genetics of psoriasis and autoimmunity","volume":"6","author":"Bowcock AM","year":"2005","unstructured":"Bowcock AM. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet. 2005, 6:93-122. 10.1146\/annurev.genom.6.080604.162324","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-003-0494-5","article-title":"Trigger factors for psoriasis [Article in German]","volume":"54","author":"Ockenfels HM","year":"2003","unstructured":"Ockenfels HM. Trigger factors for psoriasis [Article in German]. Hautarzt. 2003, 54:215-23. 10.1007\/s00105-003-0494-5","journal-title":"Hautarzt"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande R","year":"2007","unstructured":"Lande R, Gregorio J, Facchinetti V, et al.. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007, 449:564-9. 10.1038\/nature06116","journal-title":"Nature"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.06.008","article-title":"Antimicrobial peptides and self-DNA in autoimmune skin inflammation","volume":"20","author":"Gilliet M","year":"2008","unstructured":"Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol. 2008, 20:401-7. 10.1016\/j.coi.2008.06.008","journal-title":"Curr Opin Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly D","year":"2009","unstructured":"Ganguly D, Chamilos G, Lande R, et al.. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009, 206:1983-94. 10.1084\/jem.20090480","journal-title":"J Exp Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes MA","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014, 32:227-55. 10.1146\/annurev-immunol-032713-120225","journal-title":"Annu Rev Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg9012","article-title":"IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation","volume":"6","author":"Zwicky P","year":"2021","unstructured":"Zwicky P, Ingelfinger F, Silva de Melo BM, et al.. IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation. Sci Immunol. 2021, 6:eabg9012. 10.1126\/sciimmunol.abg9012","journal-title":"Sci Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig P","year":"2016","unstructured":"Kulig P, Musiol S, Freiberger SN, et al.. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016, 7:13466. 10.1038\/ncomms13466","journal-title":"Nat Commun"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0406-1","article-title":"Guselkumab: a review in moderate to severe plaque psoriasis","volume":"19","author":"Al-Salama ZT","year":"2018","unstructured":"Al-Salama ZT, Scott LJ. Guselkumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2018, 19:907-18. 10.1007\/s40257-018-0406-1","journal-title":"Am J Clin Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2023.04.006","article-title":"Unmet needs in the management of psoriasis in Latin America: a systematic review","author":"Ossanai Schoenardie B","year":"2023","unstructured":"Ossanai Schoenardie B, Oliveira Almeida R, Hanemann T, Ossanai Schoenardie A, Ribeiro AL, Catucci Boza J. Unmet needs in the management of psoriasis in Latin America: a systematic review. An Bras Dermatol. 2023, 10.1016\/j.abd.2023.04.006","journal-title":"An Bras Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al.. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017, 76:405-17. 10.1016\/j.jaad.2016.11.041","journal-title":"J Am Acad Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich K","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al.. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017, 76:418-31. 10.1016\/j.jaad.2016.11.042","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/215028-guselkumab-a-novel-monoclonal-antibody-inhibitor-of-the-p19-subunit-of-il-23-for-psoriatic-arthritis-and-plaque-psoriasis-a-review-of-its-mechanism-use-and-clinical-effectiveness","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:06:11Z","timestamp":1707491171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/215028-guselkumab-a-novel-monoclonal-antibody-inhibitor-of-the-p19-subunit-of-il-23-for-psoriatic-arthritis-and-plaque-psoriasis-a-review-of-its-mechanism-use-and-clinical-effectiveness"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,31]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.51405","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,31]]}}}